Sign inJoin Free
DashboardSign out
Free Lesson Preview
Module 1: Lesson 1
The Global Regulatory Landscape
Navigate the international framework of clinical trial regulation, from ICH harmonization to regional requirements across FDA, EMA, PMDA, and NMPA jurisdictions.
Clinical trials do not respect borders
A coordinator reviews the protocol for a new oncology trial. The sponsor is headquartered in Basel. Manufacturing occurs in Ireland. Clinical sites are distributed across the United States, Germany, Japan, and China. The investigational product will eventually be submitted for approval in all of these regions simultaneously.
This scenario is not unusual. It is, in fact, the norm for modern pharmaceutical development. And it raises an immediate practical question: whose rules apply?
The answer is both simple and complex. Simple, because a foundational principle holds across all major jurisdictions: protect research participants, ensure data reliability. Complex, because each regulatory authority has its own laws, its own procedures, its own interpretations. A clinical trial conducted in Tokyo must satisfy Japanese requirements. The same trial's Boston site must satisfy American ones. And the sponsor, hoping for simultaneous global approval, must ensure the trial satisfies everyone.
This lesson introduces the global regulatory landscape for clinical trials. You will learn how the International Council for Harmonisation works to align standards across regions, how major regulatory authorities approach clinical trial oversight, and why understanding regional differences matters for anyone working in international research.
What you will learn
By the end of this lesson, you will be able to:
You're already ahead of most
This lesson is part of a complete GCP certification track — 2 courses, quizzes, a final exam, and a certificate recognized by 18+ trial sponsors. It's entirely free.
Start your GCP certificate